Navigation Links
Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors

SKANEATELES FALLS, N.Y. and IRVINE, Calif., Feb. 8, 2011 /PRNewswire/ -- Welch Allyn and Masimo (Nasdaq: MASI) jointly announced today a new technology integration strategy that will make the Masimo rainbow® SET Pulse CO-Oximetry™ technology platform a strategic and fundamental offering in Welch Allyn's new product line-up—providing clinicians with a host of innovative new noninvasive, continuous measurements and patient monitoring capabilities.  In addition, the unique upgradeability inherent within the rainbow SET technology platform, coupled with the flexibility and configurability of next-generation Welch Allyn patient monitors, will allow clinicians the option to remotely add Masimo's noninvasive and continuous measurements as optional software upgrades as the measurements become commercially available for use with the Welch Allyn patient monitor.

"Welch Allyn is excited to provide our customers with the option of enabling the Masimo parameters within our patient monitoring devices in a manner that considers their evolving needs over time," said Welch Allyn Executive Vice President and Chief Global Business Officer, Steve Meyer.  "Masimo technology supports our platform concept of modularity and upgradeability while allowing customers to improve patient care through early, noninvasive continuous and spot check monitoring of key hemodynamic parameters."

Masimo rainbow SET noninvasive and continuous measurements—like total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and rainbow Acoustic Monitoring™ (RAM), in addition to the "gold-standard" Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR)—provide detailed physiological data that helps clinicians to more rapidly assess patients and detect adverse conditions earlier.  Pending regulatory clearance, Welch Allyn will announce the commercial availability of these rainbow SET parameters as they become legally available for use with its monitors.

Immediate availability of such detailed clinical intelligence and measurement data enables clinicians to proactively detect and treat the early signs of hemodynamic instability, potentially life-threatening conditions and internal bleeding sooner rather than reacting to late indicators and their deleterious effects.

The new Welch Allyn Connex® Vital Signs Monitor (CVSM) is the first Welch Allyn monitor to integrate the Masimo rainbow SET technology.  The CVSM, which launched in August 2010, incorporates Masimo's SpO2-enabled measurements and is capable of being field upgraded to add rainbow SET-based measurements as each parameter becomes commercially available for use with the CVSM.

The CVSM is a full-color, touch screen device that acts as three devices in one—providing comprehensive patient documentation on a single display. This documentation includes automatic measurements such as heart rate, blood pressure, temperature and pulse oximetry; manual parameters such as respiration, height, weight and pain level; and modifiers such as body position, O2 therapy details and others. The device also gives the clinician the ability to control alarms, patient data and monitoring in a customized manner for each patient, and document the data right on the device—eliminating the need to locate a PC and transcribe it later.

Welch Allyn will offer customers the ability to remotely upgrade the device's software to add additional Masimo rainbow SET capabilities via the Web using the company's innovative PartnerConnect™ Remote Services solution.  PartnerConnect is a feature of the Welch Allyn Partners in Care Services(SM) program that enables remote diagnostics of devices and systems. Software installations, updates, and upgrades can all be delivered and performed remotely. PartnerConnect also enables preemptive service capabilities on the Welch Allyn platform, allowing the Partners in Care Technical Support Center to remotely view devices and system configurations in real time via the Internet.

Masimo President of Worldwide OEM Business, Business Development, and Masimo Americas, Rick Fishel, stated, "Integrating industry-leading noninvasive and continuous monitoring technologies that offer point-of-care, cost-effective measurements and documentation is a growing trend in both continuous and spot-check patient monitors.  The Welch Allyn Connex Vital Signs Monitor represents an innovative monitoring platform in many ways, including its point-of-care configurability, upgradeability, wireless EHR connectivity, and next-generation patient monitoring capabilities—all of which help clinicians meet the patient care challenges and clinical demands of today and tomorrow.  We are proud of the positive impact our medical technology innovations have on patient care, safety, and clinical outcomes, and we are equally proud to be a key part of Welch Allyn's forward-looking patient monitoring technology strategy."

About Welch AllynFounded in 1915 and headquartered in Skaneateles Falls, NY (USA), Welch Allyn is a leading global provider of medical diagnostic equipment and a complete range of digital and connected solutions. With 2,600 employees working in 26 different countries, Welch Allyn specializes in helping doctors, nurses, and other frontline practitioners across the globe provide the best patient care by developing innovative products, breakthrough technologies, and cutting- edge solutions that help them see more patients, detect more conditions, and improve more lives. More information about Welch Allyn and its complete line of connected products and solutions may be found at

About MasimoMasimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

Forward Looking StatementsThis press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the timing and market availability of Welch Allyn products with Masimo rainbow SET technology, risks related to our assumptions that the integration of Masimo rainbow SET provides advanced noninvasive and continuous measurements and patient monitoring capabilities that have the potential to improve clinical decision-making, outcomes, and patient safety, risks related to our belief that Masimo rainbow SET measurements will enable clinicians to detect potentially life-threatening conditions earlier in all patients and clinical settings, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements.   You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.For More Information Contact:For More Information Contact:Jamie Arnold, APR

Dana BanksPublic Relations Manager

Masimo Corporation315.685.4599

SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
3. New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
4. Dehaier Medical Systems Announces New Exclusive China Distribution Agreement with Welch Allyn, Further Broadening Companys Product Lines
5. New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
6. Watson Confirms Welchol® Oral Suspension Patent Challenge
7. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
8. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
9. Pharmaxis Establishes Named Patient Program for Bronchitol
10. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
11. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):